CB-012 / Merck (MSD) - LARVOL DELTA

Cloudbreak: a novel approach for the treatment and prevention of influenza virus (ECCMID 2019) - "CB-012 demonstrated potent inhibition of viral growth vs oseltamivir in vitro. Potent CB-012 in vitro activity translated into efficacy in a lethal prophylactic mouse influenza infection model, with full protection at single doses ≥0.4 mg/kg. CB-012 displayed extended systemic exposure with a half-life of 10 days in mice."

Infectious Disease

Therapeutic Efficacy of CB-012, a Novel Cloudbreak Antiviral Fc-Conjugate (AVC) in Lethal Mouse Models of Influenza A (H1N1) and Influenza B (Victoria) (IDWeek 2019) - "In conjunction with previous findings against influenza A (H3N2), the data on CB-012 support its potential as a candidate against seasonal influenza. The continued development of CB-012 for the prevention and treatment of influenza is warranted."

Preclinical